BD to Supply Molecular Platform to BioReference

BD Diagnostics, a segment of Becton, Dickinson and Company (BD, Franklin Lakes, NJ; USA), has signed an agreement with BioReference Laboratories (BLRI, Elmwood Park, NJ, USA) whereby BD will supply BLRI with instrumentation and reagents for testing sexually transmitted infections (STIs).

Under the agreement, testing for Chlamydia trachomatis and Neisseria gonorrhoeae will be run on the Scara robotic automation platform of the BD Viper system. BD will be the primary supplier to BioReference for testing these two diseases.

The BD Viper system incorporates a Scara robot that delivers robust performance by eliminating all pumps, syringes, and tubing that were a major weakness of earlier-generation molecular automation. The isothermal, real-time amplification and detection offered by BD's strand displacement amplification (SDA) has greatly simplified complex molecular testing and made this technology more accessible to clinical laboratories.

Early and accurate diagnosis of sexually transmitted infections, specifically chlamydia and gonorrhea, leads to more timely and effective treatment, reduces the potential for further spread of infection, and helps insure better patient outcomes. Left untreated in women, chlamydia can lead to infertility, ectopic pregnancy, and debilitating pelvic pain.

BD is a medical technology company that makes and sells medical devices, instrument systems, and reagents. The company is focused on enhancing the quality and speed of diagnosing infectious diseases, improving drug therapy, advancing research, and the discovery of new drugs and vaccines. It serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public.



Related Links:
Becton, Dickinson and Company
BioReference Laboratories